Utility of gross tumor palpability or tumor size as a measure of drug efficacy for cancer prevention
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Objective
The objective of this study was to assess the concordance between
histological grading and gross tumor assessment in determining the
presence or absence of cancer in preclinical models.

Hypothesis
We hypothesized that concordance between gross palpability or histological
grading, for measuring tumor development and drug efficacy, will be poor in
non-palpable tumors.
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Summary
1. Concordance is high ( >90 %) between the two assessment methods for
palpable tumors
2. Concordance is poor ( < 40 %) between the two assessment methods for nonpalpable glands, with many of these glands harboring tumors histologically
3. Response to drug treatment is overestimated when using gross assessment of
the mammary gland as the study endpoint
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There is high concordance between tumor palpability and a higher histological
grading for palpable tumors, but poor concordance in nonpalpable glands
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The options to prevent breast cancer development are limited. Only
endocrine agents have proven efficacy of reducing the risk of ER+ breast
cancer by about 50%.
No agents are available to reduce the risk of non-ER+ breast cancers
Multiple other agents, such as lapatinib, rexinoid, and arzoxifene have
shown preventative efficacy in preclinical studies, but not for clinical
studies.
Potential reasons for this discrepancy include inherent differences
between preclinical models and human subjects, as well as the
inconsistent endpoints chosen for assessment of efficacy in preclinical
studies
Preclinical efficacy studies typically use tumor size as endpoints, as
measured by gross examination of the mammary lesions
Another measure of tumor development which is commonly used in
patients but not so much in preclinical cancer prevention studies is
histological grading
The concordance between the histologic and gross diagnosis of tumor has
not been well described
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Drug efficacy studies show significant discord between the two systems of
measuring tumor development. Histological grading is a better measure of tumor
development and drug efficacy
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Due to the lack of consistency between the two differing methods of identifying
tumor development, the use of tumor palpability as the sole endpoint measure
in chemoprevention studies should be reconsidered.

